Emma Link

A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study.

Lavinia Tan, Ben Tran, Jeanne Tie, Ben Markman, Sumi Ananda, Niall C Tebbutt, Michael Michael, Emma Link, Stephen Q Wong, Sushma Chandrashekar, Jerick Guinto, David Ritchie, Rachel Koldej, Benjamin J Solomon, Grant A McArthur, Rodney J Hicks, Peter Gibbs, Sarah-Jane Dawson, Jayesh Desai

Journal article  |  2023  |  Clin Cancer Res

PURPOSE: BRAF V600E mutant metastatic colorectal cancer represents a significant clinical problem, with combination approaches bei..

A phase 1 clinical trial of the repurposable acetyllysine mimetic, n-methyl-2-pyrrolidone (NMP), in relapsed or refractory multiple myeloma.

undefined Jake Shortt, Peter Galettis, Chan Y Cheah, Joanne Davis, Mandy Ludford-Menting, Emma K Link, Jennifer H Martin, Rachel Koldej, David Ritchie

Journal article  |  2023  |  Clin Epigenetics

BACKGROUND: N-methyl-2-pyrrolidone (NMP) is an epigenetically active chemical fragment and organic solvent with numerous applicati..

Breast radiotherapy for non-low-risk ductal carcinoma in situ: to boost or not to boost? - Authors' reply.

Boon H Chua, Emma K Link, Ian H Kunkler, Ivo A Olivotto

Journal article  |  2023  |  Lancet

1670P Circulating tumor DNA (ctDNA) dynamics of response and resistance in BRAF V600E mutant (mt) metastatic colorectal (mCRC) and other cancers: Data from EVICT (erlotinib and vemurafenib in combination trial)

L Tan, B Tran, J Tie, E Link, SQ Wong, S Chandrashekar, J Guinto, B Markman, S Ananda, NC Tebbutt, M Michael, BJ Solomon, G McArthur, P Gibbs, S-J Dawson, J Desai

Journal article  |  2022  |  Annals of Oncology

Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study.

Boon H Chua, Emma K Link, Ian H Kunkler, Timothy J Whelan, A Helen Westenberg, Guenther Gruber, Guy Bryant, Verity Ahern, Kash Purohit, Peter H Graham, Mohamed Akra, Orla McArdle, Peter O'Brien, Jennifer A Harvey, Carine Kirkove, John H Maduro, Ian D Campbell, Geoff P Delaney, Joseph D Martin, T Trinh T Vu, et al.

Journal article  |  2022  |  Lancet

BACKGROUND: Whole breast irradiation (WBI) after conservative surgery for ductal carcinoma in situ (DCIS) reduces local recurrence..

Sequential immunotherapy in rare variant renal cell carcinomafinal report of UNISoN (ANZUP 1602): Nivolumab then ipilimumab nivolumab in advanced nonclear cell renal cell carcinoma.

Ciara Conduit, Ganessan Kichenadasse, Carole A Harris, Howard Gurney, Tom Ferguson, Francis Parnis, Jeffrey C Goh, Michelle Frances Morris, Craig Underhill, David William Pook, Ian D Davis, Felicia Roncolato, Michelle L Harrison, Stephen Begbie, Anthony M Joshua, Emma Link, Elizabeth J Hovey, Craig Gedye

Journal article  |  2022  |  Journal of Clinical Oncology

4537 Background: Immune checkpoint immunotherapy (ICI) is active against many cancers. Many people are failed by PD1 inhibition a..

Increased risk of diaphragmatic herniation following esophagectomy with a minimally invasive abdominal approach

Adele Hwee Hong Lee, June Oo, Carlos S Cabalag, Emma Link, Cuong Phu Duong

Journal article  |  2021  |  DISEASES OF THE ESOPHAGUS

OBJECTIVE: Diaphragmatic herniation is a rare complication following esophagectomy, associated with risks of aspiration pneumonia,..

Evaluation of pharmacogenomics and hepatic nuclear imaging-related covariates by population pharmacokinetic models of irinotecan and its metabolites

Zheng Liu, Jennifer H Martin, Winston Liauw, Sue-Anne Mclachlan, Emma Link, Anetta Matera, Michael Thompson, Michael Jefford, Rod J Hicks, Carleen Cullinane, Athena Hatzimihalis, Ian Campbell, Simone Crowley, Phillip J Beale, Christos S Karapetis, Timothy Price, Mathew E Burge, Michael Michael

Journal article  |  2021  |  EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

BACKGROUND: Body surface area (BSA)-based dosing of irinotecan (IR) does not account for its pharmacokinetic (PK) and pharmacodyna..

Quantitative Ga-68-PSMA-11 PET/CT Parameters of Intraprostatic Malignancy in Men with Prostate Adenocarcinoma in the proPSMA Study: Comparison to ISUP Grade Group

JP Buteau, F de Galiza Barbosa, R Alipour, S Koschel, E Link, O Alghazo, C Mitchell, SF Oon, N Lawrentschuk, RJ Francis, S Williams, DG Murphy, MS Hofman

Conference Proceedings  |  2021  |  EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Ipilimumab plus nivolumab in people with rare variant renal cell carcinoma refractory to nivolumab alone: Part 2 of UNISON (ANZUP 1602) nivolumab then ipilimumab plus nivolumab in advanced non-clear cell renal cell carcinoma.

Craig Gedye, David William Pook, Laurence Eliot Miles Krieger, Carole A Harris, Jeffrey C Goh, Ganessan Kichenadasse, Howard Gurney, Craig Underhill, Francis Parnis, Anthony M Joshua, Tom Ferguson, Felicia Roncolato, Michelle L Harrison, Stephen Begbie, Michelle Frances Morris, Elizabeth J Hovey, Mathew George, Prashanth Prithviraj, Emma Link, Ian D Davis

Conference Proceedings  |  2021  |  JOURNAL OF CLINICAL ONCOLOGY

4565 Background: Immunotherapy targeting PD1 is active across many cancers, but many people are failed by PD1 inhibition alone. U..